News

MK-8931 is an oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor. Under the agreement, Luminex will leverage xMAP technology in developing the candidate device to measure

Dymista is indicated for patients 12 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief. The new nasal spray

Dr Ramachandra served as senior vice president, R&D, regulatory and medical affairs, and chief scientific officer of Hospira. Prior to Hospira, he served as vice president and oncology

This is an extention to the initial collaboration between scientists on the Florida campus of TSRI and Envoy Therapeutics in 2010 that led to several breakthroughs in identifying

The broad spectrum, oral nucleotide analog lipid-conjugate, CMX001, works by blocking the replication of double-stranded DNA (dsDNA) viruses. The company previously completed Phase II clinical development of CMX001

NC-stat DPNCheck is a quantitative point-of-care test used to detect diabetic neuropathy at an early stage. Handok expects to use both direct and indirect sales channels to promote

The company has submitted a biologics license application (BLA) to the US regulatory body based on the data from registrational Phase III hemophilia A study called A-LONG. Biogen

The firm is mulling to relocate some of the 60 staffers currently working at the site in Cambridge to Philadelphia office. GlaxoSmithKline’s spokesperson Melinda Stubbee was quoted by

The new center, which will see an investment of £20m, will include two floors and occupies 6,257m² space. The building is scheduled to be completed by late 2014